Article

Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity

2022-11-22

Abstract excerpt

Cellular immunity after SARS-CoV-2 infection or immunization may be important for long-lasting protection against severe COVID-19 disease. We investigated cellular immune responses after SARS-CoV-2 infection and/or vaccination with an interferon (IFN)-γ release assay (QuantiFERON, QFN). In parallel, we measured SARS-CoV-2 anti-Nucleocapsid (Abs-N), anti-Spike (Abs-S) and Neutralizing (NAbs) antibodies against SARS...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ef7d8b14-269a-59f7-81ea-1b3ca870f60f
DOI: 10.21203/rs.3.rs-2280174/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunityDOI 10.21203/rs.3.rs-2280174/v1Read

Real-world monitoring of BNT162b2 vaccine-induced SARS-CoV-2 B and T cell immunity in naive healthcare workers: a prospective single center studySemantic proximity Read

Anti-SARS-CoV-2 cellular immunity in 571 vaccinees assessed using an interferon-γ release assaySemantic proximity Read

Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccinationSemantic proximity Read

T Cell Responses to SARS-CoV-2Semantic proximity Read

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19Semantic proximity Read

The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing PandemicSemantic proximity Read

Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjectsSemantic proximity Read

Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodiesSemantic proximity Read

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity Read

Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS StudySemantic proximity Read

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccinationSemantic proximity Read

T cell response following anti COVID-19 BNT162b2 vaccination is maintained against the SARS-CoV-2 Omicron B.1.1.529 variant of concernSemantic proximity Read